Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This is a 6-month open-label, randomized control trial in adults to find out if certain
neuromarkers can predict individual treatment response to stimulant medications for
Attention Deficit Hyperactivity Disorder (ADHD). Males and females, ages 18-55, will be
randomized to receive either an amphetamine or a methylphenidate formulation for their ADHD.
Before beginning to receive medication treatment, each subject will complete an MRI scan at
MIT.